JP2023040219A5 - - Google Patents

Download PDF

Info

Publication number
JP2023040219A5
JP2023040219A5 JP2023002799A JP2023002799A JP2023040219A5 JP 2023040219 A5 JP2023040219 A5 JP 2023040219A5 JP 2023002799 A JP2023002799 A JP 2023002799A JP 2023002799 A JP2023002799 A JP 2023002799A JP 2023040219 A5 JP2023040219 A5 JP 2023040219A5
Authority
JP
Japan
Prior art keywords
aav
raav
itr
encoding human
aqueous suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023002799A
Other languages
English (en)
Japanese (ja)
Other versions
JP7671790B2 (ja
JP2023040219A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/020470 external-priority patent/WO2018160849A1/en
Application filed filed Critical
Publication of JP2023040219A publication Critical patent/JP2023040219A/ja
Publication of JP2023040219A5 publication Critical patent/JP2023040219A5/ja
Priority to JP2025068834A priority Critical patent/JP2025114604A/ja
Application granted granted Critical
Publication of JP7671790B2 publication Critical patent/JP7671790B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023002799A 2017-03-01 2023-01-12 眼疾患の遺伝子治療 Active JP7671790B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025068834A JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762465649P 2017-03-01 2017-03-01
US62/465,649 2017-03-01
US201762469642P 2017-03-10 2017-03-10
US62/469,642 2017-03-10
PCT/US2018/020470 WO2018160849A1 (en) 2017-03-01 2018-03-01 Gene therapy for ocular disorders
JP2019547457A JP7211960B2 (ja) 2017-03-01 2018-03-01 眼疾患の遺伝子治療

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019547457A Division JP7211960B2 (ja) 2017-03-01 2018-03-01 眼疾患の遺伝子治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025068834A Division JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Publications (3)

Publication Number Publication Date
JP2023040219A JP2023040219A (ja) 2023-03-22
JP2023040219A5 true JP2023040219A5 (enExample) 2023-06-26
JP7671790B2 JP7671790B2 (ja) 2025-05-02

Family

ID=63370488

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019547457A Active JP7211960B2 (ja) 2017-03-01 2018-03-01 眼疾患の遺伝子治療
JP2023002799A Active JP7671790B2 (ja) 2017-03-01 2023-01-12 眼疾患の遺伝子治療
JP2025068834A Pending JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019547457A Active JP7211960B2 (ja) 2017-03-01 2018-03-01 眼疾患の遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025068834A Pending JP2025114604A (ja) 2017-03-01 2025-04-18 眼疾患の遺伝子治療

Country Status (11)

Country Link
US (2) US11564996B2 (enExample)
EP (2) EP4656244A2 (enExample)
JP (3) JP7211960B2 (enExample)
KR (3) KR20240104196A (enExample)
CN (2) CN119752819A (enExample)
AU (2) AU2018228881B2 (enExample)
BR (1) BR112019017327A2 (enExample)
CA (1) CA3054136A1 (enExample)
IL (2) IL314284A (enExample)
RU (1) RU2019130004A (enExample)
WO (1) WO2018160849A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019296451B2 (en) * 2018-06-29 2021-04-29 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
JP7640549B2 (ja) * 2019-12-12 2025-03-05 ノバルティス アーゲー 注射デバイス及び注射溶液移し替えシステム
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
US20220387627A1 (en) * 2021-06-03 2022-12-08 Hope for Hasti Vectors and gene therapy for treating cornelia de lange syndrome

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
DE69824859T2 (de) 1997-04-14 2005-08-04 Cell Genesys, Inc., Foster City Methoden zur erhöhung der effizienz rekombinanter aav produkte
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
DE60039766D1 (de) 1999-08-09 2008-09-18 Targeted Genetics Corp Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
EP1381276A4 (en) * 2001-04-13 2005-02-02 Univ Pennsylvania METHOD FOR TREATMENT OR DEVELOPMENT SLUDGE DEGRADATION
CA2915124C (en) 2001-11-13 2018-08-14 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
ES2602352T3 (es) 2001-12-17 2017-02-20 The Trustees Of The University Of Pennsylvania Secuencias de serotipo 8 de virus adenoasociado (VAA), vectores que las contienen y usos de las mismas
WO2003104413A2 (en) 2002-06-05 2003-12-18 University Of Florida Production of pseudotyped recombinant aav virions
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
EP1660970A4 (en) 2003-08-01 2007-02-14 Dna Twopointo Inc SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
EP2298926A1 (en) 2003-09-30 2011-03-23 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
EP2357010B1 (en) 2005-04-07 2013-06-12 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
US7456683B2 (en) 2005-06-09 2008-11-25 Panasonic Corporation Amplitude error compensating device and quadrature skew error compensating device
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
WO2008065430A2 (en) * 2006-12-01 2008-06-05 Oxford Biomedica (Uk) Limited Promoter construct
MX353900B (es) 2008-11-07 2018-02-01 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
US20120172419A1 (en) * 2009-09-15 2012-07-05 Medical College Of Wisconsin Research Foundation Inc. Reagents and methods for modulating cone photoreceptor activity
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
SG10201502270TA (en) 2010-03-29 2015-05-28 Univ Pennsylvania Pharmacologically induced transgene ablation system
WO2012158757A1 (en) 2011-05-16 2012-11-22 The Trustees Of The University Of Pennsylvania Proviral plasmids for production of recombinant adeno-associated virus
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
BR112014020325A2 (pt) * 2012-02-17 2017-08-08 Childrens Hospital Philadelphia composições de vetor do aav e métodos para a transferência de gene para as células, órgãos e tecidos
WO2013182683A1 (en) 2012-06-08 2013-12-12 Ethris Gmbh Pulmonary delivery of messenger rna
CA2878171C (en) 2012-07-11 2021-04-27 The Trustees Of The University Of Pennsylvania Aav-mediated gene therapy for rpgr x-linked retinal degeneration
EP2883981A4 (en) 2012-08-08 2016-05-11 Nihon Parkerizing METAL SURFACE TREATMENT LIQUID, SURFACE TREATMENT METHOD FOR A METAL BASE, AND METAL BASE OBTAINED BY THE SURFACE TREATMENT PROCESS FOR METAL BASIS
US9567376B2 (en) 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
WO2014140051A1 (en) * 2013-03-11 2014-09-18 Fondazione Telethon Mir-204 and mir-211 and uses thereof
EP2970943A4 (en) * 2013-03-15 2017-04-19 The Children's Hospital of Philadelphia Vectors comprising stuffer/filler polynucleotide sequences and methods of use
US9158889B2 (en) 2013-04-26 2015-10-13 Oral4D Systems Ltd. Electronic dental charting
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
WO2015009575A1 (en) * 2013-07-16 2015-01-22 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of disorders related to cep290
WO2016019364A1 (en) * 2014-08-01 2016-02-04 The Trustees Of The University Of Pennsylvania Compositions and methods for self-regulated inducible gene expression

Similar Documents

Publication Publication Date Title
JP2023040219A5 (enExample)
JP2020510428A5 (enExample)
Lai et al. Adenovirus and adeno-associated virus vectors
JP2019513794A5 (enExample)
JP2024054426A5 (enExample)
JP2021121638A5 (enExample)
JP2020514286A5 (enExample)
M Mitchell et al. AAV's anatomy: roadmap for optimizing vectors for translational success
RU2018136611A (ru) Генная терапия для лечения гемофилии a
ES2685611T3 (es) Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
ES2256265T3 (es) Vectores de parvovirus duplicados.
ES2640586T3 (es) Secuencias del factor VIII
JP2018537984A5 (enExample)
TW201629225A (zh) 第九因子基因療法
Stilwell et al. Adeno-associated virus vectors for therapeutic gene transfer
Yla-Herttuala et al. Improving safety of gene therapy
WO2002053703A2 (en) Aav2 vectors and methods
JP2020519292A5 (enExample)
JPWO2020210655A5 (enExample)
CN111225677A (zh) 单采血液分离方法和用途
JP2020503265A5 (enExample)
JP2019524090A5 (enExample)
JP2024056832A5 (enExample)
JP2024119830A5 (enExample)
JP2018526994A5 (enExample)